A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Trial end date:
2020-08-14
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter,
exploratory Phase 2 study including participants with Idiopathic Pulmonary Fibrosis (IPF),
investigating GLPG1205 in addition to the local standard of care (defined as receiving
nintedanib, pirfenidone, or neither nintedanib nor pirfenidone).